{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:19:58Z","timestamp":1774541998085,"version":"3.50.1"},"reference-count":35,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"DOI":"10.1210\/jc.2006-1526","type":"journal-article","created":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T03:23:38Z","timestamp":1169609018000},"page":"1296-1304","source":"Crossref","is-referenced-by-count":161,"title":["Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"92","author":[{"given":"Pierre D.","family":"Delmas","sequence":"first","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) Research Unit 831 and Universite\u0301 Claude Bernard Lyon 1 (P.D.D.), 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Vrijens","sequence":"additional","affiliation":[{"name":"AARDEX Ltd. (B.V.), CH-6302 Zug, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Metabolic Bone Centre (R.E.), Northern General Hospital, South Yorkshire S5 7AU, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[{"name":"Department of Rheumatology (C.R.), Paris-Descartes University, Cochin Hospital, 75014 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibert A. P.","family":"Pols","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (H.A.P.P.), Department of Internal Medicine, Erasmus MC, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann D.","family":"Ringe","sequence":"additional","affiliation":[{"name":"Klinikum Leverkusen (J.D.R.), 51375 Leverkusen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Grauer","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals (A.G.), Mason, Ohio 45040"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cahall","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis (D.C.), Bridgewater, New Jersey 08807"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[{"name":"University of Cincinnati Bone Health and Osteoporosis Center (N.B.W.), Cincinnati, Ohio 45219"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113443129900_R1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989.","volume":"7","author":"Cooper","year":"1992","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R2","first-page":"2","article-title":"Osteoporosis: epidemiology, diagnosis, and treatment.","volume":"93","author":"Iqbal","year":"2000","journal-title":"South Med J"},{"key":"key\n\t\t\t\t2019041113443129900_R3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy.","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113443129900_R4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","article-title":"Compliance with treatment regimens in chronic asymptomatic diseases.","volume":"102","author":"Miller","year":"1997","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113443129900_R5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11906-996-0034-7","article-title":"Hypertension and current issues in compliance and patient outcomes.","volume":"2","author":"Zyczynski","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"key\n\t\t\t\t2019041113443129900_R6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archinte.164.7.722","article-title":"How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials.","volume":"164","author":"Schroeder","year":"2004","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113443129900_R7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0149-2918(01)80152-1","article-title":"Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.","volume":"23","author":"Conlin","year":"2001","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041113443129900_R8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients.","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113443129900_R9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes.","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113443129900_R10","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113443129900_R11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00198-003-1431-2","article-title":"Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.","volume":"14","author":"Papaioannou","year":"2003","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113443129900_R12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0149-2918(04)90023-9","article-title":"Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study.","volume":"26","author":"Turbi","year":"2004","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041113443129900_R13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis.","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"key\n\t\t\t\t2019041113443129900_R14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.18553\/jmcp.2004.10.2.142","article-title":"Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.","volume":"10","author":"Watts","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t2019041113443129900_R15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice.","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113443129900_R16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-8510(01)00178-6","article-title":"A review of the literature on the economics of noncompliance. Room for methodological improvement.","volume":"59","author":"Cleemput","year":"2002","journal-title":"Health Policy"},{"issue":"Suppl 6","key":"key\n\t\t\t\t2019041113443129900_R17","first-page":"S2","article-title":"The use of biochemical markers of bone turnover in osteoporosis","volume":"11","author":"Delmas","year":"2000","journal-title":"Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113443129900_R18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113443129900_R21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique.","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/JBMR.041214","article-title":"Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study.","volume":"20","author":"Delmas","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113443129900_R24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113443129900_R25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113443129900_R26","first-page":"128","article-title":"Design and analysis of cluster randomization trials in health design","author":"Donner","year":"2000","journal-title":"London: Arnold, a member of the Hodder Headline Group;"},{"key":"key\n\t\t\t\t2019041113443129900_R27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"2 Pt 1","key":"key\n\t\t\t\t2019041113443129900_R28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1164\/ajrccm.149.2.8306018","article-title":"Monitoring for adherence: ethical considerations","volume":"149","author":"Levine","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2019041113443129900_R29","doi-asserted-by":"crossref","unstructured":"Rand CS, Sevick MA2000 Ethics in adherence promotion and monitoring. Control Clin Trials 21(5 Suppl):241S\u2013247S","DOI":"10.1016\/S0197-2456(00)00085-4"},{"key":"key\n\t\t\t\t2019041113443129900_R30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1378\/chest.118.2.290","article-title":"Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial.","volume":"118","author":"Simmons","year":"2000","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041113443129900_R31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0005-7967(03)00149-9","article-title":"Electronic monitoring and counseling to improve medication adherence.","volume":"42","author":"Rosen","year":"2004","journal-title":"Behav Res Ther"},{"key":"key\n\t\t\t\t2019041113443129900_R32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.yebeh.2004.02.002","article-title":"Medication management by the person with epilepsy: perception versus reality.","volume":"5","author":"Buelow","year":"2004","journal-title":"Epilepsy Behav"},{"key":"key\n\t\t\t\t2019041113443129900_R33","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1001\/jama.288.22.2880","article-title":"Helping patients follow prescribed treatment: clinical applications.","volume":"288","author":"Haynes","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113443129900_R34","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1001\/jama.288.22.2868","article-title":"Interventions to enhance patient adherence to medication prescriptions: scientific review.","volume":"288","author":"McDonald","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113443129900_R35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-001-0023-4","article-title":"Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons.","volume":"3","author":"Deal","year":"2001","journal-title":"Curr Rheumatol Rep"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/4\/1296\/9052548\/jcem1296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T01:58:07Z","timestamp":1628387887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/4\/1296\/2597032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-1526","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}